<DOC>
	<DOCNO>NCT02564900</DOCNO>
	<brief_summary>This open-label , two-part , multiple study evaluate safety tolerability DS-8201a patient advance solid malignant tumor .</brief_summary>
	<brief_title>Study DS-8201a Subjects With Advanced Solid Malignant Tumors</brief_title>
	<detailed_description>This study one single group participant two period . It therefore randomize . The dosage strength change study participant receive study drug DS-8201a . So study true 2 arm study , 2 part study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group performance status ( PS ) 0 1 . Left Ventricular Ejection Fraction ( LVEF ) â‰¥ 50 % Part 1 : Advanced/unresectable metastatic breast cancer gastric gastroesophageal junction adenocarcinoma refractory intolerable standard treatment , standard treatment available . Part 2a : Advanced breast cancer HER2 overexpression refractory intolerable standard treatment , standard treatment available . Treated adotrastuzumab emtansine ( TDM1 ) Part 2b : Advanced gastric gastroesophageal junction adenocarcinoma HER2 overexpression refractory intolerable standard treatment , standard treatment available . Treated trastuzumab Part 2c : Advanced breast cancer HER2 low expression refractory intolerable standard treatment , standard treatment available . Part 2d : Advanced solid malignant tumor HER2 expression breast cancer gastric gastroesophageal junction adenocarcinoma refractory intolerable standard treatment , standard treatment available . Has medical history symptomatic Congestive Heart Failure ( CHF ) ( NYHA class IIIV ) serious cardiac arrhythmia . Has medical history myocardial infarction unstable angina . Has QTc prolongation &gt; 450 millisecond ( m ) males &gt; 470 m female . Has medical history clinically significant lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>phase 1</keyword>
	<keyword>oncology</keyword>
	<keyword>HER2</keyword>
	<keyword>Antibody drug conjugate ( ADC )</keyword>
</DOC>